Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Toxicity Conditioning for CBT in Pediatric AML
NCT00887042Phase 2Unknown
- Sponsor
- Korean Society of Pediatric Hematology-Oncology
- Start
- Jun 2006
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and antithymocyte globulin rabbit in acute myeloid leukemia (AML), sponsored by Korean Society of Pediatric Hematology-Oncology. Primary endpoints: Engraftment potential, Treatment Related Mortality and 1 more. Status: unknown.
02
Drugs
fludarabinebusulfanantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00887042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887042.